Thomas Jefferson University

Jefferson Digital Commons
Department of Neurology Faculty Papers

Department of Neurology

1-1-2018

Advances in the diagnosis, immunopathogenesis and therapies of
IgM-anti-MAG antibody-mediated neuropathies.
Marinos Dalakas
Neuromuscular Division, Department of Neurology, Thomas Jefferson University, 901 Walnut Street,
Philadelphia, PA, United States; Neuroimmunology Unit, Department of Pathophysiology, National and
Kapodistrian University of Athens Medical School, Athens, Greece

Follow this and additional works at: https://jdc.jefferson.edu/neurologyfp
Part of the Neurology Commons

Let us know how access to this document benefits you
Recommended Citation
Dalakas, Marinos, "Advances in the diagnosis, immunopathogenesis and therapies of IgM-antiMAG antibody-mediated neuropathies." (2018). Department of Neurology Faculty Papers. Paper
150.
https://jdc.jefferson.edu/neurologyfp/150
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Neurology Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

746640
review-article2018

TAN0010.1177/1756285617746640Therapeutic Advances in Neurological DisordersMC Dalakas

Therapeutic Advances in Neurological Disorders

Review

Advances in the diagnosis,
immunopathogenesis and therapies of
IgM-anti-MAG antibody-mediated
neuropathies

Ther Adv Neurol Disord
2018, Vol. 11: 1–12
https://doi.org/10.1177/1756285617746640
DOI: 10.1177/
https://doi.org/10.1177/1756285617746640
1756285617746640

© The Author(s), 2018.
Reprints and permissions:
http://www.sagepub.co.uk/
journalsPermissions.nav

Marinos C. Dalakas

Abstract: Polyneuropathy with immunoglobulin M (IgM) monoclonal gammopathy is the most
common paraproteinemic neuropathy, comprising a clinicopathologically and immunologically
distinct entity. The clinical spectrum spans from distal paresthesias and mild gait imbalance
to more severe sensory ataxia, with falls and a varying degree of distal sensorimotor deficits.
In approximately 75% of patients, the monoclonal IgM immunoreacts with myelin-associated
glycoprotein (MAG) and sulfoglucuronyl glycosphingolipid (SGPG), or other peripheral nerve
glycolipids that serve as antigens. These antibodies are considered pathogenic because IgM
and complement are deposited on the myelin sheath, splitting the myelin lamellae, while
adoptive transfer of patients’ IgM into susceptible host animals causes sensory ataxia and
reproduces the human pathology. In spite of the apparently convincing pathogenicity of these
antibodies, the response to immunotherapies remains suboptimal. Clorambuscil, cladibrine,
cyclophospamide and intravenous immunoglobulin may help some patients but the benefits
are minimal and transient. Open-label studies in >200 patients indicate that rituximab is
helpful in 30–50% of these patients, even with long-term benefits, probably by suppressing
IgM anti-MAG antibodies or inducing immunoregulatory T cells. Two controlled studies with
rituximab did not however meet the primary endpoint, mostly because of the poor sensitivity
of the scales used; they did however show statistical improvement in secondary endpoints
and improved clinical functions in several patients. This review provides an overview of the
clinical phenotypes and immunoreactivity of IgM to glycolipids or glycoproteins of peripheral
nerve myelin, summarizes the progress on treatment with rituximab as a promising therapy,
discusses the pitfalls of scales used, identifies possible biomarkers of response to therapy
and highlights the promising new anti-B cell or target-specific immunotherapies.

Keywords: polyneuropathy; anti-MAG antibodies; autoimmune neuropathies; neuropathy with
monoclonal gammopathy; rituximab; anti-B cell therapies
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Introduction
Benign monoclonal gammopathies, often called
‘monoclonal gammopathies of undetermined significance’ (MGUS), occur in up to 1% of normal
people over the age of 50, with age-increasing
incidence up to 1.7% above the age of 70 and 6%
above 90.1 Monoclonal gammopathies are however 10 times more frequent in patients with polyneuropathy than age-matched controls, and 10%
of adults with acquired polyneuropathy have a
monoclonal gammopathy.2,3 If the gammopathies

are categorized into immunoglobulin G (IgG),
IgA and IgM subclasses, the incidence of polyneuropathy among patients with IgM monoclonal
gammopathy can be as high as 50%, implying
that 50% of patients with IgM MGUS may have
or develop polyneuropathy.3,4 The association is
not therefore fortuitous; it is also of importance to
neurologists because paraproteinemic polyneuropathies comprise a potentially treatable group
of autoimmune neuropathies, as proposed >35
years ago.5
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Figure 1. Cross-section of a sural nerve biopsy from a patient with immunoglobulin M antimyelin-associated
glycoprotein antibody demyelinating polyneuropathy.

The biopsy specimen is stained with toluidine blue and shows selective loss of large-size myelinated fibers (left); histogram
(right) depicting the fiber-size distribution of the patient’s nerve (yellow), overlapped with the fiber-size distribution (blue)
from normal data, clearly demonstrating the selective loss of large-size fibers.

Although paraproteinemic polyneuropathies can
be seen in a setting of lymphoid malignancy such
as myeloma, plasmacytoma, or Waldenström’s
macroglobulinemia, most neuropathies recognized first by neurologists occur in connection
with MGUS. The term MGUS was coined by
hematologists to denote that the gammopathy is
‘of no significance’ when there is no hematological
disease; in a patient with neuropathy however,
MGUS is ‘of significance’ because, even if benign,
the gammopathy may point to an immune association possibly amenable to immunotherapy.5,6
The patients who have a demyelinating polyneuropathy associated with IgG or IgA–MGUS
behave like chronic inflammatory demyelinating
polyneuropathy (CIDP) and the paraprotein is
likely coincidental; in contrast, patients with polyneuropathy and IgM MGUS have distinct clinicopathologic and immunobiologic phenotypes.
This review describes the clinical spectrum and
highlights the progress in the immunopathogenesis and treatment of IgM–MGUS neuropathy, the
most common paraproteinemic neuropathy.
Clinical spectrum
Patients with IgM–MGUS typically manifest
symptoms associated with dysfunction or loss of
large myelinated fibers, most often presented with
slowly progressive distal paresthesias, prominent
in the feet, and impaired balance. The disease
progresses very slowly, leading to impaired proprioception, sensory ataxia, unsteady gait, and a
varying degree of distal muscle weakness, first
seen in toe and foot extensors.4–6 A good number
2

of patients have an action tremor prominent in
the hands that is unrelated to impaired proprioception.7,8 The clinical spectrum varies substantially; some patients have only distal paresthesias
and minimal gait imbalance that may not sufficiently affect daily activities or cause disability
that could be captured with disability scales, as
discussed;9 others manifest sensory ataxia and
impaired gait; and still others have a combination
of sensorimotor deficits with slowly progressive
proximal and distal weakness that along with sensory ataxia, cause significant disability.6,9,10 Some
patients may have subacute onset and faster
disease course resembling CIDP with mixed
features of demyelination and axonal loss.11
Immunofixation electrophoresis reveals an IgM
monoclonal spike that remains present throughout the course, although at times becomes faint or
temporarily undetectable; the total IgM may be
normal, but is usually elevated three-to-five times
above normal. The Cerebrospinal fluid (CSF)
protein is often elevated. The IgM spike is also
detected in the CSF and exhibits the same electrophoretic mobility as in the serum, in spite of
the high-molecular weight of IgM, probably gaining access via the dorsal root ganglia that lack
blood–CSF barrier or from a disrupted root–CSF
barrier.12 Nerve-conduction studies demonstrate
a uniformly slow conduction velocity with a rather
characteristic prolonged distal motor and sensory
latencies, indicative of distal demyelination.13,14
Sural nerve biopsy shows diminished numbers of
myelinated axons with selective loss of large myelinating fibers, consistent with the clinical picture
of impaired proprioception (Figure 1). Electron
microscopy demonstrates a rather unique
journals.sagepub.com/home/tan
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splitting of the outer myelin lamellae, probably
linked to the presence of IgM deposits in the same
area of the split myelin sheaths.15
Clinical evaluation
The first goal is to ensure that the gammopathy is
MGUS and not a sign of an underlying plasma cell
dyscrasia, such as myeloma, plasmacytoma, or
Waldenström’s macroglobulinemia. Monoclonal
gammopathies are hematologically benign
(MGUS) when the patients have: (a) <3 g/dl monoclonal protein in the serum; (b) no signs of renal
insufficiency, osteolytic or osteosclerotic lesions in
the bone survey, and signs of anemia or hypercalcemia; (c) no suppression of the uninvolved (IgG,
IgA) polyclonal (background) Igs; and (d) stable
amount of the monoclonal protein in follow-up
examinations.5,6,16 When ominous signs of malignant plasma cell dyscrasia are detected, such as
lytic bone lesions, Bence-Jones proteinuria, or
progressively increased amount of monoclonal
protein, a bone marrow examination is essential;
the presence of >5% plasma cells and 12% lymphoid aggregates suggests malignancy. Because
there is a 1% probability per year that MGUS may
evolve into plasma cell dyscrasia,1 yearly follow-up
examinations with immunofixation electrophoresis
and Ig levels are necessary.16 Finding a free light
chain should raise suspicion of amyloidosis derived
from the variable region of the immunoglobulin
light chain, mostly λ. Amyloid neuropathy is painful and often accompanied by autonomic symptoms, such as orthostatic hypotension, impotence,
impaired
gastric
motility,
or
diarrhea.
Diagnostically, deposits of amyloid may be found
in the nerve and muscle biopsy, skin, abdominal
fat or bone marrow.16
Immunopathogenesis
Antimyelin-associated glycoprotein antibodies
The main breakthrough in this neuropathy was the
discovery by Latov and colleagues of IgM immunoreactivity to myelin-associated glycoprotein
(MAG), a 100 kDa glycoprotein of the central and
peripheral nerve myelin.17 Sera from approximately
50% of these patients react with MAG or with
acidic glycolipids that share antigenic determinants
with MAG10,16–19 and reside in the carbohydrate
component of the MAG molecule, as we have
demonstrated by loss of reactivity after deglycosylation of purified MAG18 (Figure 2A). An important
observation was the subsequent finding that the
anti-MAG IgM coreacts with an acidic glycolipid
journals.sagepub.com/home/tan

in the ganglioside fraction of the human peripheral
nerve, which by ion-exchange chromatography was
seen between monosialotetrahexosylganglioside
bearing one sialic acid (GM1) and bearing two
sialic acids (GD1a) and identified as a SGPG19
(Figure 2B). In contrast to MAG, which is present
in both, the peripheral nervous system (PNS) and
the central nervous system (CNS), SGPG is found
exclusively in the peripheral nerves. SGPG also
recognizes the human natural killer-1 (HNK-1) trisaccharide epitope, present on both MAG and
other peripheral nerve glycoconjugates.20
Human anti-MAG antibodies can be detected in
the patients’ sera with enzyme-linked immunosorbent assay (ELISA) or Western blots by electrophoresing purified MAG, isolated myelin, or
whole brain homogenates.19,20 Because sera positive for anti-MAG antibodies almost always recognize the SGPG glycolipid, the assay has been
performed by certain laboratories using SGPG as
antigen instead of human MAG. It is clearly preferable to use MAG instead of SGPG because the
IgM antibodies bind to MAG 10–100 times more
strongly than to SGPG; consequently, low-affinity
anti-MAG antibodies may be missed if SGPG is
used as antigen.16,19,20 In a large series of patients’
samples, the presence of MAG antibodies detected
by ELISA was the most preferable assay because it
was sensitive and easier than Western blotting.22
Other antiganglioside antibodies
In some patients with neuropathy clinically identical to IgM-anti-MAG phenotype, the serum
may not react with MAG or SGPG, but only
with various gangliosides most commonly those
containing either a disialosyl moiety (e.g. GD1b,
GQ1b, GT1b, the GalNac-GM1b, or Gal-NAcGD1a) or two gangliosides that share epitopes
with GM2, a combination of GM2 and GM1, or
GM1 and GD1b.21,23–25 Overall, more than half
of the IgM paraproteins recognize MAG and
SGPG, and 75% of the rest recognize ganglioside
antigens, indicating that acidic glycolipids are the
most common antigenic epitopes in immunemediated neuropathies, as depicted in Figure
2C.21,23–26
Causal relationship between antimyelinassociated glycoprotein/sulfoglucuronyl
glycosphingolipid antibodies and the
neuropathy
Because MAG is present only in small amounts
in the peripheral nerves, compared with its
3
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Figure 2. Immunoreactivity of patients’ immunoglobulin M to myelin-associated glycoprotein and glycolipids.

(A) Immunoblots of sodium dodecyl sulfate gels with purified MAG extracted from rat (R) or human (H), are stained for
protein with Am Bl (left) or immunostained with the serum of a patient with IgM MGUS neuropathy (middle lane). The
patient’s IgM binds only to purified human MAG (middle lane; Per Neu); the reactivity is identical to the band obtained with
a commercial MAb to human MAG (right) (from Dalakas16 and Ilyas et al19). (B) TLC overlay experiments show that the
IgM from an anti-MAG-reacting patient recognizes glycolipid antigens of human peripheral nerve. The panel on the left
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Figure 2. (Continued)
shows resorcinol-stained ganglioside fractions isolated from human brain (CNS) or from human peripheral nerve (PNS).
The prominent gangliosides are labelled for reference. The panel on the right shows an autoradiograph obtained from
overlaying the same TLC plate with the patient’s serum followed by radiodinated antihuman IgM. The major glycolipid
antigen recognized by the patients’ IgM (arrow) is SGPG found exclusively in the PNS. SGPG is between two minor glycolipid
antigens (shown on the left gel) migrating above and below SGPG (from Dalakas16 and Ilyas et al.19). (C) Common glycolipids
and their disialosyl moieties, consisting of NeuAca2-8NeuAc, that serve as antigens in autoimmune neuropathies The SGPG
is most common in anti-MAG-neuropathy; the GM1 in MMN; the GD1a and GT1b with two sialic acid residues, and the GT1b
immunoreact with 25% of MAG-reactive patients who have IgM-MGUS and ataxic neuropathy; the GQ1b ganglioside (with two
disialosyl moieties) is the most specifc target antigen in Miller-Fisher syndrome (from Dalakas and Quarles21).
MAG, myelin-associated glycoprotein; Am Bl, amido black; IgM, immunoglobulin M; MGUS, monoclonal gammopathies of
undetermined significance; TLC, thin layer chromatography; MAb, monoclonal antibody; RESO, resorsinol; CNS, central
nervous system; PNS, peripheral nervous system; SGPG, sulfoglucuronyl glycosphingolipid; GM1, bearing one sialic
acid; MMN, Multifocal Motor Neuropathy; GD1a, bearing two sialic acids; GT1b, ganglioside with three sialic acids; GQ1b,
ganglioside with four sialic acids.

abundance in the CNS (which is spared in these
patients), the immunoreactivity of IgM to MAG
was considered by some as a nonpathogenic,
binding to antigens with carbohydrate epitopes.
The discovery of PNS-specific SGPG glycolipid
however, that all anti-MAG-positive patients
immunoreact with, has strengthened the view
that glycolipids, along with glycoproteins, may
be the primary antigenic targets.9,10,16,26,27 The
following factors provide convincing evidence
that these antibodies are causally related to the
neuropathy:
(1) Sural nerve biopsies demonstrate deposition
of IgM and complement on the myelinated nerve
fibers,28 suggesting that activated complement is
needed to induce demyelination.
(2) The patients’ IgM recognizes neural cell adhesion molecules and co-localizes with MAG on the
split myelin lamellae,15,16,26,27,29 implying involvement of IgM in myelin disadhesion. This view is
strengthened by observations on the patients’ skin
biopsies which showed deposits of IgM, complement C3d, and MAG on the dermal myelinated
fibers associated with reduction of intraneural
nerve fiber density.29
(3) The patients’ whole serum or purified IgM,
when injected with fresh complement into feline
peripheral nerves, causes complement-dependent
demyelination and conduction block within 2–9
days.30
(4) Systemic administration of anti-MAG IgM
paraprotein in chickens, causes segmental peripheral nerve demyelination with deposition of IgM
on the outer myelin lamellae and splitting of the
myelin sheath in a pattern similar to the one
observed in the human neuropathy.31

journals.sagepub.com/home/tan

(5) Immunization of cats with purified SGPG
causes ataxic neuropathy, clinically resembling
the anti-MAG/SGPG sensory ataxic phenotype,
with inflammation within the dorsal root ganglionic neurons.32
Treatment
In patients with IgG or IgA MGUS who have an
axonal neuropathy, the paraprotein is probably of
unknown significance; if their neuropathy however is demyelinating, it should be treated as
CIDP. In these patients, a causal relationship
between the IgG or IgA MGUS and the neuropathy has not been established because in contrast
to IgM-MGUS, the A and G immunoglobulins
do not recognize MAG or other antigens, except
rarely when they recognize complex glycolipids,
as shown in one of our patients with IgA
gammopathy.33
Since the IgM-anti-MAG antibodies appear to
exert a pathogenic effect on the myelin structure
and function,34,35 it was expected that suppressing
their production, removal of the antibodies or
modification of the immune network should have
a therapeutic effect. Unfortunately, this is not the
case in clinical practice because conventional
immunotherapies and chemotherapies offer marginal or transient benefit,26,27,35–42 necessitating
the need for more specific therapies.
When to initiate therapy
The aforementioned clinical spectrum and disease severity should be taken into account in therapeutic decisions. Patients who only have distal
paresthesias without gait difficulties that affect
daily activities, should be managed with supportive therapy consisting of exercise and balance
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training. If, however, manifest gait ataxia, falls
and muscle weakness, or present with a CIDPlike picture from the outset, they should be treated
early before permanent deficits due to axonal
degeneration take place.36–42
Chemotherapeutic agents
Chlorambucil and prednisone, a combination
used to treat Waldenström’s macroglobulinemia,
can improve or stabilize a small number of
patients, as we have witnessed in one,43 but the
benefit is minimal and does not often outweigh
the risks.37–42
Oral cyclophosphamide, in a randomized controlled
trial of 35 patients (500 mg for 4 days) in combination with 60 mg prednisolone, every 4 weeks for 6
months, showed some improvements in the Medical
Research Council (MRC) sumscores,44 but methodological problems with the study design and
malignant transformation observed in 10% diminished the impact of the outcome.44
Fludarabine, applied to 16 patients in an openlabel study, showed transient benefits in some
patients45,46 and significant adverse effects in 4.
Intravenous immunoglobulin
In three anti-MAG-positive patients we treated
with intravenous immunoglobulin (IVIG),47 an
improvement in motor and sensory functions was
observed, prompting us to conduct the first controlled study. Among 11 randomized patients, the
neuropathy scores improved in three patients; the
overall differences between IVIG and placebo were
not however significant.48 A small multicenter
study conducted in Europe, in spite of some methodological issues, showed modest benefits that
were statistically significant only for the secondary
outcome measures.49,50 In an uncontrolled study in
patients with sensory ataxic neuropathy associated
with anti-GD1b, but not anti-MAG, antibodies,
IVIG showed short-term benefits.51 Overall, the
benefits from IVIG have been minimal.50
Rituximab: a promising anti-B-cell therapy for
antimyelin-associated glycoprotein neuropathy
Rituximab is a monoclonal antibody against
CD20, a B-cell surface antigen present on pre-B
cells and throughout the B-cell life cycle, but not
on plasma cells.52–54 Rituximab causes depletion
of circulating B cells, prompting several trials.
6

Figure 3. Effect of rituximab in the time to 10 m walk
in a double-blind study.64
Difference in the 10 m walk time by repeated-measures
analysis of variance between the rituximab and placebo
groups. A significantly improved gait was seen in the
rituximab group (yellow) compared with placebo (p = 0.042)
(red) in the intention-to-treat analysis.

Uncontrolled studies. First tried in a rather heterogeneous group of 21 patients, rituximab improved
most patients 1 year after treatment and reduced
IgM autoantibodies.55,56 In another, prospective,
open-label study, six of nine patients improved after
12 months with improved electrophysiology and
reduced anti-MAG antibodies.57 Using double the
standard dose (750 mg/kg every week for 1 month,
instead of 375 mg/kg), the same authors noted
improvement in four of eight additional patients.58
Cumulative data from approximately 200 patients
treated in the last 15 years show that rituximab
helped 30–50% of the patients.36,59–63 In most, IgM
levels decreased by 39% and anti-MAG by 68%.60
Controlled studies. In spite of the above promising observations, two controlled studies, using
different scales and endpoints, have not convincingly captured this benefit. In the first doubleblind placebo-controlled study of 26 patients, 13
were randomized to rituximab and 13 to placebo.64 The primary endpoint was a change of
>1 in Inflammatory Neuropathy Cause and
Treatment (INCAT) leg disability score at
month 8. By intention-to-treat (ITT), 4/13
(30%) of rituximab-randomized patients
improved by >1 INCAT score, compared with
0/13 placebo-receiving patients (p = 0.096). One
of the patients randomized to rituximab however,
was found to have a normal INCAT score
at entry and could not improve; if this patient
is excluded, the results become significant
journals.sagepub.com/home/tan

MC Dalakas

Figure 4. Reduction of B cells, immunoglobulin M, and antimyelin-associated glycoprotein after rituximab in a
controlled study.
(A, B) The IgM levels are decreased by 34% (A) and the anti-MAG antibody titers by >50% (B), most prominently at month
8, in rituximab-treated patients compared with placebo; (C, D) Kinetics of depletion and reappearance of CD20+ B cells (C)
and the CD20+ CD27+ memory B cells (D) in rituximab-treated patients compared with placebo. B cells are depleted in the
periphery by month 2 and start rebounding by month 6; the CD20+ CD27+ memory B cells start reappearing a little later by
month 8 (D), often consistent with the need for reinfusion if there are early signs of clinical relapse.64
IgM, immunoglobulin M; MAG, myelin-associated glycoprotein; APC, antigen-presenting cell, PE, PRE (pre-B cells).

(p = 0.036). The time to 10 m walk, a secondary
endpoint, was significantly reduced in the rituximab-randomized group by ITT (Figure 3). On
clinical grounds, walking and daily activities
improved in 7/13 (53.8%) rituximab-treated
patients, compared with 0/13 placebo-treated
ones, reaching a percentage similar to the one
observed in cumulative uncontrolled series, as
mentioned earlier. The serum IgM was reduced
by 34% and the anti-MAG titers by 50%64
(Figure 4A–B). In this series, the most improved
patients were those who had high anti-MAG
titers and most severe sensory deficits. The main
drawback of the study was the scales used;
INCAT is a disability motor scale and could not
effectively capture small functional changes in
sensory function, especially mild gait impairment
and sensory ataxia.
Important useful data regarding the immunobiology of B cells and antibody production were
observed in clinically-improved patients.
Because the signs of clinical response coincided
with depletion of B cells and reduction of antiMAG antibodies (Figure 4A–C), rituximab (that
journals.sagepub.com/home/tan

does not affect plasma cells), has likely depleted
the memory B cells, which are the precursors of
short-lived plasma cells. Indeed, the memory
CD20+ CD27+ B cells were depleted 1 month
after rituximab infusion and remained undetectable for 6 months; they started reappearing by
month 8 and coincided with the slow rise of IgM
serum level (Figure 4A–D). Study of B cell Ig
gene usage between the four responders compared with nonresponders, revealed clonal
expansions of circulating IgM memory B cells
that recognized MAG antigen.65 Most importantly, in the nonrituximab responders, the load
of IgM memory B cells and the CDR3 clonally
expanded sequences were higher and persisted
before and after therapy, a finding we interpreted
to suggest that low efficiency to reduce B-cell
expansions may be associated with poor clinical
response.65 Accordingly, higher doses of rituximab (as shown in patients who improved with
double dosage),58 or more potent B-celldepleting agents that reduce further the clonally
related autoreactive B cells may be more effective.36 A significant increase of Foxp3-positive
immunoregulatory T cells was also observed at 8
7
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months, suggesting that rituximab affected the
immunoregulatory T-cell balance.64
A second, much larger controlled study, was conducted in 54 patients, 26 randomized to rituximab and 28 to placebo.66 Using sensory scales as
primary endpoint at month 12, the authors did
not capture any benefit; they did, however,
observe a significant response in secondary endpoints based on disability and time-to-walk
scales.67 The discrepancy between the two wellconducted clinical trials is obviously related to
patient selection and scales used, highlighting the
inadequacy of sensory INCAT to capture and
quantify small, but clinically meaningful, changes
related to gait ataxia.
Possible biomarkers of patient subsets
responding to rituximab
Obviously, the question is not anymore whether
rituximab is helpful or not, but why it benefits
<50% of the patients and whether there are biomarkers predicting response.36 Demyelinating
pattern, absence of treatment and older age were
significant risk factors for disability worsening,62
while predominantly motor deficits and subacute
progression were associated with positive
response.11 Gender, ataxia, tremor and IgM antiMAG antibody titers were observed to be irrelevant in predicting response;11,60,62 in one study,
recurrence of disease correlated best with high
baseline anti-MAG titers and increasing antiMAG antibodies at follow up.63
Avidity, and variability in binding of anti-MAG/
SGPG antibodies to target antigens, is a factor
possibly
explaining
different
therapeutic
responses.68 Serum levels of BAFF (B-cell activating factor), a key costimulatory molecule for B-cell
survival, proliferation and immunoglobulin production,52,54 were higher in anti-MAG patients not
responding to rituximab;61 BAFF increased post
rituximab in those who responded but, in those
who relapsed, BAFF returned to baseline, suggesting that BAFF may be useful in predicting
responses and relapses.61 The finding that therapeutic efficacy depends on reconfiguration of
memory B cells through sustained reduction of
autoreactive clonal expansions,65 could also explain
why rituximab is effective in only a patient subset.
The need for retreatment to maintain stability in
patients with prior response to rituximab may be
monitored by the B27-memory B cells that start
re-emerging after 8 months64 (Figure 4D).
8

Safety profile
Notwithstanding the benefit of rituximab for certain patient subsets, potential side effects should be
considered.36,52,54 Rituximab may at times worsen
anti-MAG neuropathy,69,70 a phenomenon we have
also witnessed in three patients; this is probably
related to immunomodulatory imbalance and
release of proinflammatory cytokines that could
possibly change the permeability of the blood–
nerve barrier allowing the influx of IgM antibodies
within the nerve.36,70 This worsening is rare or selflimited and is almost always reversed by IVIG.
Rituximab has an excellent safety profile, but infections from common bacteria or viral agents can
occur.36,52–54 Progressive multifocal leukoencephalopathy has been reported in some patients with
B-cell malignancies receiving rituximab plus chemotherapy
(R-CHOP,
fludarabine).36,52,54,71
Vigilance is recommended, especially in patients
receiving concomitant immunosuppressants.
The future: new drugs, better scales, and
antigen-specific therapies
Anti-B-cell agents
If rituximab helps 30–50% of anti-MAG neuropathy patients, the newer anti-B-cell agents
that cause more profound or sustained B-cell
depletion, could theoretically be more encouraging.36,52,54 B cells not only affect complement
activation and antibody production but are
strong antigen-presenting cells affecting
autoregulation and T-cell activation,52,54 which
explains the benefit of rituximab to diseases
with dominant T-cell receptor gene usage.54,72
Occrelizumab, the humanized version of rituximab that induces more complement activation,
is approved for multiple sclerosis and should be
considered. Ofatumumab that targets two different epitopes on CD20 causes more significant B-cell depletion; it appears promising in
multiple sclerosis (MS) and could be another
candidate drug. Obinituzumab, a humanized
monoclonal against CD20 approved for chronic
lymphocytic leukemia, causes profound B-cell
depletion; the drug, recently tried in two antiMAG neuropathy patients resistant or partially
responding to rituximab did not show efficacy,
in spite of reducing the IgM levels and
anti-MAG titers.73 Belimumab against the
B-lymphocyte stimulator BLyS, approved for
lupus, may be another alternative, although its
failure in MS and myasthenia gravis, lowers its
priority status.36,54
journals.sagepub.com/home/tan
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Scales
Because the disease exhibits a wide clinical spectrum, future studies should include patients with
homogeneous clinical phenotypes and disease
duration. Patients with very slowly progressing
disease develop secondary axonal changes over
time and worsening ataxia, with loss of ganglionic
neurons; as a result, these patients are less likely
to respond compared with patients having more
recent disease and subacute progression.11
Applying functional scales to capture even minor
impairments in life activities, gait imbalance and
hand tremors is fundamental. For example, in
our controlled study,64 more patients were able to
perform additional daily activities after rituximab
compared with placebo, experienced steadier and
faster walking, better balance, easier use of utensils, and fewer falls, pain or paresthesias; none of
these changes could be however numerically captured with the INCAT disability scales.64
Hand tremor
The tremor seen in many anti-MAG patients can
be incapacitating. It is a neuropathic tremor,
unrelated to impaired proprioception or a coexisting cerebellar disease; it is unresponsive to conventional antiessential tremor drugs but can
improve in some patients responding to immunotherapy. Unilateral thalamic deep brain stimulation (DBS) applied in one patient unresponsive to
plasma exchange, cyclophosphamide, steroids,
primidone, and gabapentin, induced sustained
improvement.73 DBS interferes with cerebellar
circuits implicated in tremor generation; because
in anti-MAG patients the cerebellum may receive
disordered sensory input,75 DBS needs further
study.
Antigen-specific therapy
Anti-MAG antibodies are thought to interfere
directly with MAG’s involvement in adhesion
and signaling processes at the axon–glia interface76 resulting in cellular disadhesion. Because
MAG has a higher HNK-1 epitope density than
other myelin glycoconjugates leading to strong
IgM antibody binding, removal of HNK with
synthetized glycopolymers may prevent binding
of anti-MAG IgM to human MAG.76 On this
basis, in a mouse model for anti-MAG neuropathy, the glycopolymer PL84(mimHNK-1),
designed as an autoantibody scavenger by mimicking the natural HNK-1 glycoepitope, effectively removed the pathogenic anti-MAG
journals.sagepub.com/home/tan

antibodies, offering promising potential for antigen-specific immunotherapy.77
Funding
This research received no specific grant from any
funding agency in the public, commercial, or notfor-profit sectors.
Conflict of interest statement
The author declares that there is no conflict of
interest.

References
1. Kyle RA, Therneau TM, Rajkumar SV, et al.
Prevalence of monoclonal gammopathy of
undetermined significance. N Engl J Med 2006;
354: 1362–1369.
2. Kelly JJ, Kyle RA, O’Brien PC, et al. The
prevalence of monoclonal gammopathy in
peripheral neuropathy. Neurology 1981; 31:
1480–1483.
3. Kelly JJ. Peripheral neuropathies associated with
monoclonal gammopathies of undetermined
significance. Rev Neurol Dis 2008; 5: 14–22.
4. Latov N, Hays A and Sherman WH. Peripheral
neuropathy and anti-MAG antibodies. Crit Rev
Neurobiol 1988; 3: 301–332.
5. Dalakas MC and Engel WK. Polyneuropathy and
monoclonal gammopathy: studies of 11 patients.
Ann Neurol 1981; 10: 45–52.
6. Dalakas MC. Pathogenesis of autoimmune
neuropathies. Biochim Biophys Acta 2015; 1852:
658–666.
7. Dalakas MC. Chronic idiopathic ataxic
neuropathy. Ann Neurol 1986; 19: 545–554.
8. Dalakas MC, Teravinen H and Engel WK.
Tremor as a feature of chronic relapsing and
dysgammaglobulinemic polyneuropathies:
incidence and management. Arch Neurol 1984;
41: 711–714.
9. Dalakas MC. Pathogenesis and treatment of
anti-MAG neuropathy. Curr Treat Options Neurol
2010; 12: 71–83.
10. Latov N and Renaud S. Effector mechanisms
in anti-MAG antibody-mediated and other
demyelinating neuropathies. J Neurol Sci 2004;
220: 127–129.
11. Gazzola S, Delmont E, Franques J, et al.
Predictive factors of efficacy of rituximab in
patients with anti-MAG neuropathy. J Neurol Sci
2017; 377: 144–148.

9

Therapeutic Advances in Neurological Disorders 11
12. Dalakas MC and Papadopoulos NM.
Paraproteins in the spinal fluid of patients with
paraproteinemic polyneuropathies. Ann Neurol
1984; 15: 590–593.
13. Kaku DA, England JD and Sumner AJ.
Distal accentuation of conduction slowing in
polyneuropathy associated with antibodies to
myelin-associated glycoprotein and sulphated
glucuronyl paragloboside. Brain 1994; 117(Pt 5):
941–947.
14. Lupu VD, Mora CA, Dambrosia J, et al. Median
terminal Latency Index differentiates anti-MAG/
SGPG neuropathy from HMSN1. Muscle Nerve
2007; 35: 196–202.
15. Vallat JM, Tabaraud F, Magy L, et al. Diagnostic
value of nerve biopsy for atypical chronic
inflammatory demyelinating polyneuropathy:
evaluation of eight cases. Muscle Nerve 2003; 27:
478–485.
16. Dalakas MC. Autoimmune peripheral
neuropathies. In: Rich RR, Fleisher TA, Shearer
WT, et al. (eds) Clinical immunology: principles and
practice. 3rd ed. Oxford: Mosby Elsevier, 2008,
pp.977–994.
17. Latov N, Braun PE, Gross RB, et al. Plasma
cell dyscrasia and peripheral neuropathy:
identification of the myelin antigens that react
with human paraproteins. Proc Natl Acad Sci USA
1981; 78: 7139–7142.
18. Ilyas AA, Quarles RH, McIntosh TD, et al.
IgM in a human neuropathy related to
paraproteinemia binds to a carbohydrate
determinant in the myelin associated glycoprotein
and to a ganglioside. Proc Natl Acad Sci USA
1984; 81: 1225–1229.
19. Ilyas AA, Quarles RH, Dalakas MC, et al.
Polyneuropathy with monoclonal gammopathy:
glycolipids are frequently antigens for IgM
paraproteins. Proc Natl Acad Sci USA 1985; 82:
6697–6700.
20. Quarles RH. Myelin-associated glycoprotein
(MAG): past, present and beyond. J Neurochem
2007; 100: 1431–1448.
21. Dalakas MC and Quarles RH. Autoimmune
ataxic neuropathies (sensory ganglionopathies):
are glycolipids the responsible autoantigens? Ann
Neurol 1996; 39: 419–422.
22. Kuijf ML, Eurelings M, Tio-Gillen AP,
et al. Detection of anti-MAG antibodies in
polyneuropathy associated with IgM monoclonal
gammopathy. Neurology 2009; 73: 688–695.
23. Ilyas AA, Li SC, Chou DKH, et al. Gangliosides
GM2, IV4Gal NaC GM1B, and IV4Gal
NaC GD1a as antigens for monoclonal

10

immunoglobulin M neuropathy associated with
gammopathy. J Biol Chem 1988; 263: 4369–
4373.
24. Duane GC, Farrer RG, Dalakas MC, et al.
Sensory neuropathy associated with monoclonal
IgM to GD1b ganglioside. Ann Neurol 1992; 31:
683–685.
25. Quarles RH and Dalakas MC. Do antiganglioside
antibodies cause human peripheral neuropathies?
J Clin Invest 1996; 97: 1136–1137.
26. Latov N. Pathogenesis and therapy of
neuropathies associated with monoclonal
gammopathies. Ann Neurol 1995; 37: S32–S42.
27. Steck AJ, Stalder AK and Renaud S. Anti-myelinassociated glycoprotein neuropathy. Curr Opin
Neurol 2006; 19: 458–463.
28. Monaco S, Bonetti B, Ferrari S, et al.
Complement dependent demyelination in
patients with IgM monoclonal gammopathy
and polyneuropathy. N Engl J Med 1990; 322:
844–852.
29. Lombardi R, Erne B, Lauria G, et al. IgM
deposits on skin nerves in anti-myelin-associated
glycoprotein neuropathy. Ann Neurol 2005; 57:
180–187.
30. Willison HJ, Trapp BD, Bacher JD, et al.
Demyelination induced by intraneural injection
of human antimyelin associated glycoprotein
antibodies. Muscle Nerve 1988; 11: 1169–1176.
31. Tatum AH. Experimental paraprotein
neuropathy, demyelination by passive transfer of
human IgM anti-MAG. Ann Neurol 1993; 33:
502–506.
32. Ilyas AA, Gu Y, Dalakas MC, et al. Induction
of experimental ataxic sensory neuronopathy
in cats by immunization with purified SGPG. J
Neuroimmunol 2008; 193: 87–93.
33. Farrer RG, Dalakas MC and Quarles RH.
Multiple antibodies to nerve glycoconjugates
in an unusual patient with neuropathy and
monoclonal IgA gammopathy. J Neuroimmunol
1996; 66: 71–76.
34. Vallat JM, Jauberteau MO, Bordessoule D,
et al. Link between peripheral neuropathy and
monoclonal dysglobulinemia: a study of 66 cases.
J Neurol Sci 1996; 137: 124–130.
35. Vallat JM, Magy L, Ciron J, et al. Therapeutic
options and management of polyneuropathy
associated with anti-MAG antibodies. Expert Rev
Neurother 2016; 16: 1111–1119.
36. Dalakas MC. Rituximab an anti-MAG
neuropathy: more evidence for efficacy and

journals.sagepub.com/home/tan

MC Dalakas
more predictive factors. J Neurol Sci 2017; 377:
224–226.

in demyelinating neuropathy with IgM
gammopathy. Ann Neurol 1996; 40: 792–795.

37. Magey L, Kabore R, Mathis S, et al.
Heterogeneity of polyneuropathy associated with
anti-MAG antibodies. J Neuroimmunol Res 2015;
2015: 450391.

49. Comi G, Roveri L, Swan A, et al. A randomized
controlled trial of intravenous immunoglobulin
in IgM paraprotein associated demyelinating
neuropathy. J Neurol 2002; 249: 1370–1377.

38. Dalakas MC. Clinical Trials in CIDP
and Chronic Autoimmune Demyelinating
Polyneuropathies. J Peripher Nerv Syst 2012;
(suppl 2): 34–39.

50. Dalakas MC. The use of intravenous
immunoglobulin in the treatment of autoimmune
neurological disorders: evidence-based
indications and safety profile. Pharmacol Ther
2004; 102: 177–193.

39. Nobile-Orazio E, Meucci N, Baldini L, et al.
Long-term prognosis of neuropathy associated
with anti-MAG IgM M-proteins and its
relationship to immune therapies. Brain 2000;
123(Pt 4): 710–717.

51. Attarian S, Boucraut J, Hubert AM, et al.
Chronic ataxic neuropathies associated with antiGD1b IgM antibodies: response to IVIg therapy.
J Neurol Neurosurg Psychiatry 2010; 81: 61–64.

40. Leger JM, Guimaraes-Costa R and Muntean
C. Immunotherapy in peripheral neuropathies.
Neurotherapeutics 2016; 13: 96–107.

52. Dalakas MC. B cells as therapeutic targets in
autoimmune neurological disorders. Nat Clin
Pract Neurol 2008; 4: 557–567.

41. Lunn MP and Nobile-Orazio E. Immunotherapy
for IgM anti-myelin-associated glycoprotein
paraprotein-associated peripheral neuropathies.
Cochrane Database Syst Rev 2016; 10: CD002827.

53. Kosmidis M and Dalakas MC. Rituximab in the
treatment of neurological disorders. Ther Adv
Neurol Disord 2010; 3: 93–105.

42. Steck AJ, Czaplinski A and Renaud S.
Inflammatory demyelinating neuropathies and
neuropathies with monoclonal gammopathies:
treatment update. Neurotherapeutics 2008; 5:
528–534.
43. Dalakas MC, Flaum MA, Rick M, et al.
Treatment of polyneuropathy in Waldenström’s
macroglobulinemia: role of paraproteinemia
and immunological studies. Neurology 1983; 33:
1406–1410.
44. Niermeijer JM, Eurelings M, van der Linden
MW, et al. Intermittent cyclophosphamide with
prednisone versus placebo for polyneuropathy
with IgM monoclonal gammopathy. Neurology
2007; 69: 50–59.
45. Wilson HC, Lunn MP, Schey S, et al. Successful
treatment of IgM paraproteinaemic neuropathy
with fludarabine. J Neurol Neurosurg Psychiatry
1999; 66: 575–580.
46. Niermeijer JM, Eurelings M, Lokhorst H,
et al. Neurologic and hematologic response
to fludarabine treatment in IgM MGUS
polyneuropathy. Neurology 2006; 67: 2076–
2079.
47. Cook D, Dalakas M, Galdi A, et al. High-dose
intravenous immunoglobulin in the treatment
of demyelinating neuropathy associated with
monoclonal gammopathy. Neurology 1990; 40:
212–214.
48. Dalakas MC, Quarles RH, Farrer RG, et al. A
controlled study of intravenous immunoglobulin

journals.sagepub.com/home/tan

54. Alexopoulos H, Biba A and Dalakas MC. AntiB-Cell therapies in autoimmune neurological
diseases: rationale and efficacy trials.
Neurotherapeutics 2016; 13: 20–33.
55. Levine TD and Pestronk A. IgM antibody-related
polyneuropathies: B-cell depletion chemotherapy
using rituximab. Neurology 1999; 52: 1701–1704.
56. Pestronk A, Florence J, Miller T, et al. Treatment
of IgM antibody associated polyneuropathies
using rituximab. J Neurol Neurosurg Psychiatry
2003; 74: 485–489.
57. Renaud S, Gregor M, Fuhr P, et al. Rituximab in
the treatment of polyneuropathy associated with
anti-MAG antibodies. Muscle Nerve 2003; 27:
611–615.
58. Renaud S, Fuhr P, Gregor M, et al. Highdose rituximab and anti-MAG-associated
polyneuropathy. Neurology 2006; 66: 742–744.
59. Benedetti L, Briani C, Grandis M, et al.
Predictors of response to rituximab in patients
with neuropathy and anti-myelin associated
glycoprotein immunoglobulin. J Peripher Nerv
Syst 2007; 12: 102–107.
60. Benedetti L, Briani C, Franciotta D, et al.
Long term effect of rituximab in anti-MAG
polyneuropathy. Neurology 2008; 71:
1742–1744.
61. Benedetti L, Zardini E, Briani C, et al. B-cellactivating factor in rituximab-treated patient with
anti-MAG polyneuropathy. J Neurol Neurosurg
Psychiatry 2011; 82: e1291–e1294.

11

Therapeutic Advances in Neurological Disorders 11
62. Galassi G, Tondelli M, Ariatti A, et al. Longterm disability and prognostic factors in
polyneuropathy associated with anti-myelinassociated glycoprotein (MAG) antibodies. Int J
Neurosci 2017; 127: 439–447.
63. Campagnolo M, Zambello R, Nobile-Orazio E,
et al. IgM MGUS and Waldenstrom-associated
anti-MAG neuropathies display similar response
to rituximab therapy. J Neurol Neurosurg
Psychiatry. Epub ahead of print 13 May 2017.
DOI: 10.1136/jnnp-2017-315736.
64. Dalakas MC, Rakocevic G, Salajegheh M, et al.
Placebo-controlled trial of rituximab in IgM
anti-myelin associated glycoprotein antibody
demyelinating neuropathy. Ann Neurol 2009; 65:
286–293.
65. Maurer MA, Rakocevic G, Leung CS, et al.
Rituximab induces sustained reduction of
pathogenic B cells in patients with peripheral
nervous system autoimmunity. J Clin Invest 2012;
122: 1393–1402.
66. Léger JM, Viala K, Nicolas G, et al. Placebocontrolled trial of rituximab in IgM anti-myelinassociated glycoprotein neuropathy. Neurology
2013; 80: 2217–2225.
67. Ferfoglia R, Guimaraes-Costa R, Viala K, et al.
Long-term efficacy of rituximab in IgM antmyelin-associated glycoprotein neuropathy:
RIMAG follow-up study. J Peripher Nerv Syst
2016; 21: 10–14.
68. Weiss MD, Dalakas MC, Lauter CJ, et al.
Variability in the binding of anti-MAG and
anti-SGPG antibodies to target antigens
in demyelinating neuropathy and IgM
paraproteinemia. J Neuroimmunol 1999; 95:
174–184.

Visit SAGE journals online
journals.sagepub.com/
home/tan

SAGE journals

12

69. Broglio L and Lauria G. Worsening after
rituximab treatment in anti-mag neuropathy
[letter]. Muscle Nerve 2005; 32: 378–379.
70. Vo ML, Martin P and Latov N. Correlation of
changes in Gait parameters, with phenotype,

outcome measures, and electrodiagnostic
abnormalities in a patient with anti-MAG
neuropathy after exacerbation and improvement.
J Clin Neuromuscul Dis 2015; 17: 22–26.
71. Bonavita S, Conforti R, Russo A, et al. Infratentorial
progressive multifocal leukoencephalopathy in a
patient treated with fludarabine and rituximab.
Neurol Sci 2008; 29: 37–39.
72. O’Hanlon TP, Dalakas MC, Plotz PH, et al.
Predominant a/b T cell receptor variable and
joining gene expression by muscle-infiltrating
lymphocytes in the idiopathic inflammatory
myopathies. J Immunol 1994; 152: 2569–2576.
73. Rakocevic G, Martinez A, Dalakas MC.
Obinutuzumab (GAZYVA), a Potent Anti-B
Cell Agent, in the Treatment of RituximabUnresponsive IgM Anti-Myelin-AssociatedGlycoprotein (MAG)-Mediated-Neuropathy
(submitted to the American Academy of
Neurology annual meeting April 2018).
74. McMaster J, Gibson G, Castro-Prado F, et al.
Neurosurgical treatment of tremor in antimyelinassociated glycoprotein neuropathy. Neurology
2009; 73: 1707–1708.
75. Weeks RA, Gerloff C, Dalakas MC, et al. PET
study of visually and non-visually guided finger
movements in patients with severe pan-sensory
neuropathies and healthy controls. Exp Brain Res
1999; 128: 291–302.
76. Burger D, Perruisseau G, Simon M, et al.
Comparison of the N-linked oligosaccharide
structures of the two major human myelin
glycoproteins MAG and P0: assessment of the
structures bearing the epitope for HNK-1 and
human monoclonal immunoglobulin M found in
demyelinating neuropathy. J Neurochem 1992; 58:
854–861.
77. Herrendorff R, Hänggi P, Pfister H, et al.
Selective in vivo removal of pathogenic anti-MAG
autoantibodies, an antigen-specific treatment
option for anti-MAG neuropathy. Proc Natl Acad
Sci USA 2017; 114: E3689–E3698.

journals.sagepub.com/home/tan

